Article
Biochemistry & Molecular Biology
Yanan Shi, Qing Wei, Yajin Liu, Jihong Yuan
Summary: Sphingosine kinase 2 (SphK2) inhibitors, such as K145, have shown significant effects in reducing hepatic lipid accumulation and improving liver function in obese and diabetic mice. These inhibitors work by inhibiting lipogenesis and promoting mitochondrial fatty acid beta-oxidation, offering potential in developing drugs for non-alcoholic fatty liver disease and diabetes therapy.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Shu-Ju Wu, Wen-Chung Huang, Ming-Chin Yu, Ya-Ling Chen, Szu-Chuan Shen, Kuo-Wei Yeh, Chian-Jiun Liou
Summary: Tomatidine, derived from the leaves and green fruits of plants in the Solanaceae family, has been shown to exhibit anti-inflammatory and antitumor effects. It reduces lipid accumulation in the liver, decreases body and fat weight, and improves nonalcoholic fatty liver disease. Additionally, tomatidine regulates lipid metabolism and promotes lipolysis through the sirt1/AMPK signaling pathway.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Daiane T. Oliveira, Adriano B. Chaves-Filho, Marcos Y. Yoshinaga, Nivia Carolina N. Paiva, Claudia M. Carneiro, Sayuri Miyamoto, William T. Festuccia, Renata Guerra-Sa
Summary: The chronic consumption of a high-sugar diet induces lipid overload, oxidative stress, and impaired fatty acid oxidation in the liver, leading to the development of nonalcoholic fatty liver disease (NAFLD). This study provides comprehensive insights into the pathogenesis of NAFLD induced by high-sugar diet consumption under energy-balanced conditions.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY
(2021)
Article
Nutrition & Dietetics
Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
Summary: The present study suggests that Diosgenin (DIO) protects against type II diabetes-associated nonalcoholic fatty liver disease (D-NAFLD) by inhibiting hepatic de novo lipogenesis, improving dyslipidemia, and enhancing mitochondrial function.
Article
Pharmacology & Pharmacy
Fanrong Zhao, Lei Zhang, Menglin Zhang, Jincan Huang, Jun Zhang, Yongsheng Chang
Summary: This study found that FGF9 expression was increased in the livers of diet-induced obese mice, and knockdown exacerbated the fatty liver phenotype while overexpression alleviated hepatic steatosis and improved insulin sensitivity. Mechanistically, FGF9 inhibits genes involved in lipogenesis and increases genes involved in fatty acid oxidation, reducing cellular lipid accumulation.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Suwen Chen, Shangwen Sun, Yanan Feng, Xiu Li, Guoliang Yin, Pengpeng Liang, Wenfei Yu, Decheng Meng, Xin Zhang, Hongshuai Liu, Fengxia Zhang
Summary: Nonalcoholic fatty liver disease (NAFLD) is a common liver disease without approved treatment. Hepatic farnesoid X receptor (FXR) is a potential therapeutic target for NAFLD. Diosgenin (DG), a natural compound from Chinese herbal medicine, effectively prevents metabolic diseases. Our research reveals that DG can alleviate NAFLD by regulating the hepatic FXR-SHP-SREBP1C/PPARa/CD36 pathway.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Jiayao Feng, Shuting Qiu, Shipeng Zhou, Yue Tan, Yan Bai, Hua Cao, Jiao Guo, Zhengquan Su
Summary: This paper explores the various mechanisms by which mTOR regulates lipid metabolism, insulin resistance, oxidative stress, intestinal microbiota, autophagy, inflammation, genetic polymorphisms, and epigenetics in NAFLD. The research suggests that mTOR plays a crucial role in the development of NAFLD and provides new therapeutic targets.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Mahak Arora, Nikolina Kutinova Canova, Hassan Farghali
Summary: This review provides a brief overview of the mechanism behind the progression of non-alcoholic fatty liver disease (NAFLD) to chronic non-alcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular cancer. The review highlights the potential of targeting mTOR as a treatment for NASH, due to its significant role in lipogenesis and alleviating inflammation and fibrosis.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Yumiko Okano Tamura, Jun Sugama, Shinji Iwasaki, Masako Sasaki, Hironobu Yasuno, Kazunobu Aoyama, Masanori Watanabe, Derek M. Erion, Hiroaki Yashiro
Summary: The study demonstrated that a novel selective inhibitor of acetyl-CoA carboxylase (ACC) 1 has anti-nonalcoholic fatty liver disease (NAFLD) and anti-nonalcoholic steatohepatitis (NASH) effects in preclinical models. Treatment with this compound significantly improved hepatic steatosis and fibrosis in a mouse model, supporting its potential as a new treatment for NAFLD/NASH.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2021)
Article
Pharmacology & Pharmacy
Yuting Ma, Guangdong Zhang, Zenggguang Kuang, Qian Xu, Tongtong Ye, Xue Li, Na Qu, Fang Han, Chengxia Kan, Xiaodong Sun
Summary: Empagliflozin (EMPA) therapy has been shown to improve non-alcoholic fatty liver disease (NAFLD) patients. This study investigated the functional implications of EMPA on the pathogenesis of NAFLD and identified the underlying molecular mechanisms. The results showed that EMPA treatment reversed liver damage by upregulating Sestrin2 and activating the AMPK-mTOR pathway, leading to the inhibition of lipogenesis and inflammation. These findings suggest that EMPA therapy could target Sestrin2 to alleviate lipogenesis and inflammation in obesity-related NAFLD.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yang Hai, Ling Zuo, Meng Wang, Ruoyu Zhang, Munan Wang, Li Ren, Congwen Yang, Jianwei Wang
Summary: This study found that icariin has an ameliorative effect on hepatic steatosis induced by polycystic ovary syndrome. It reduces excess testosterone and lipid metabolites, increases the expression of fatty acid oxidation molecules, and decreases lipid synthesis.
Article
Biochemistry & Molecular Biology
Laia Bertran, Laia Adalid, Merce Vilaro-Blay, Andrea Barrientos-Riosalido, Carmen Aguilar, Salome Martinez, Fatima Sabench, Daniel del Castillo, Jose Antonio Porras, Ajla Alibalic, Cristobal Richart, Teresa Auguet
Summary: Nonalcoholic fatty liver disease (NAFLD) is a common chronic hepatic disease. This study evaluated the role of STING in NAFLD by analyzing STING mRNA abundance and protein expression in liver biopsies. The results showed that STING mRNA expression in the liver increases with the occurrence of NAFLD, especially in the stage of simple steatosis. Protein analysis confirmed these results and revealed positive correlations with liver enzymes, Toll-like receptor 9 expression, and microbiota-derived bile acids.
Review
Biochemistry & Molecular Biology
Raghu Ramanathan, Ahmad Hassan Ali, Jamal A. Ibdah
Summary: Nonalcoholic fatty liver disease (NAFLD) is a global pandemic strongly associated with metabolic syndromes. Metabolic-associated fatty liver disease (MAFLD) is suggested as a more appropriate term to describe the disease, emphasizing the role of metabolic dysfunction. Mitochondrial dysfunction plays a significant role in NAFLD development and targeting mitochondria shows promise for drug development.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Engineering, Environmental
Shouchun Xiao, Jingna Cui, Aisong Chen, Haonan Hou, Jianing Yao, Yue Cao, Yaofeng Fang, Xueke Liu, Zhiqiang Zhou, Donghui Liu, Peng Wang
Summary: This study comprehensively investigates the impact of pesticide exposure on thyroid and liver health. The results indicate that famoxadone induces hepatic steatosis and oxidative stress, leading to NAFLD. Furthermore, famoxadone disrupts thyroid hormone synthesis and transport. These findings reveal the association between NAFLD and thyroid dysfunction, providing new insights for the health risk assessment of pesticides.
ENVIRONMENTAL SCIENCE & TECHNOLOGY
(2023)
Review
Cell Biology
X. Charlie Dong
Summary: SIRT6 is a member of the sirtuin protein family and plays a crucial role in regulating hepatic lipid metabolism and homeostasis. It negatively regulates lipogenesis and positively affects fatty acid oxidation through multiple mechanisms. SIRT6 also modulates cholesterol synthesis and inflammation in the liver. Furthermore, it has anti-fibrosis effects and can have both tumor-suppressive and tumor-promoting activities in liver cancer.